The Lipitor deal had further added to the speculation of Pfizer picking up a stake in Ranbaxy. But Pfizer on June 18 said that it has no intention of picking up stake in Ranbaxy. It described the Liptor deal, in which Ranbaxy would be allowed to launch generic versions of Lipitor before the patent on the drug expires, as pro-patient as well as a win-win situation for both companies. Earlier, on the same day Ranbaxy announced that it has settled its long-running dispute with Pfizer on the cholesterol-fighting drug, Lipitor, which is also among the world''s highest selling drug. The value accruing to Ranbaxy from one of the biggest settlements in the global pharma industry is seen exceeding $1.5 billion, say sources. The settlement covers key markets in eight countries, including the US. Lipitor has global annual sales of around $12 billion, with US sales exceeding $8 billion. Ranbaxy would also benefit from a substantial savings in legal costs from the Pfizer settlement
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment